Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.74 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.74 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.74 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.74 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.74 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.74 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480443 | 0.89 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5480439 | 0.89 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3750013 | 0.87 | MAP1LC3B (0.69) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477805 | 0.85 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477806 | 0.85 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395354 | 0.85 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395352 | 0.85 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3800644 | 0.85 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13452839 | 0.84 | LRRK2 (0.57) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18499298 | 0.84 | LRRK2 (0.72) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | claimed |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | US | claimed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | LRRK2 39/4885PSEN1 18/4885PSEN2 9/4885 |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, BDNF, HTT | LRRK2 26/4885PSEN1 15/4885PSEN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.